Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Scie…
Biotechnology
US, Minneapolis [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Bio-Techne Corporation (TECH) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 39,172.65 | 13,906.84 | 641.52 | 395.31 | -1,152.95 | 0.00 | 24.1385 | 45.41 | -0.9009 | -21.2239 | -0.08 | -0.08 | 6.7010 | - - | ||
| Maximum | - - | - - | - - | 1,535,067.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
| Halozyme Therapeutics, Inc. HALO | 45.70 | -0.06 -0.13% | 1,268 vs. 1,580 | 5,814.00 | 195.00 | 76.00 | 125.00 | 167.00 | 0.6100 | 17.0691 | 0.0000 | 0.7647 | 0.3922 | 0.4321 | 0.0417 | 5.0088 | 127.00 | ||
| Exelixis, Inc. EXEL | 34.83 | 0.18 0.52% | 1,318 vs. 2,065 | 9,946.00 | 425.00 | 37.00 | 50.00 | -258.00 | 0.1200 | 47.8131 | 0.0000 | 0.9500 | 0.0878 | 0.0175 | 0.0133 | 3.2273 | 285.00 | ||
| Akero Therapeutics, Inc. AKRO | 31.20 | 0.57 1.84% | 522 vs. 551 | 2,177.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
| Blueprint Medicines Corporation BPMC | 96.62 | 1.81 1.91% | 741 vs. 620 | 6,137.00 | 96.00 | 89.00 | -102.00 | -2,250.00 | 1.4500 | 16.6530 | 0.0000 | 0.9168 | 0.9274 | 0.2869 | 0.0858 | 3.4266 | 63.00 | ||
| United Therapeutics Corporation UTHR | 367.36 | 3.03 0.83% | 201 vs. 363 | 16,400.00 | 677.00 | 306.00 | 338.00 | 6,333.00 | 6.5200 | 8.7477 | 0.0000 | 0.8924 | 0.4524 | 0.0574 | 0.0472 | 3.5035 | 44.00 | ||
| Nuvalent, Inc. NUVL | 92.73 | 1.56 1.71% | 389 vs. 533 | 6,588.00 | 0.00 | -44.00 | -36.00 | -330.00 | -0.6900 | -27.7942 | 0.0000 | 0.0000 | 0.0000 | -0.0659 | -0.0628 | 20.6970 | 71.00 | ||
| BioMarin Pharmaceutical Inc. BMRN | 63.45 | 0.89 1.42% | 1,230 vs. 1,774 | 12,092.00 | 648.00 | 88.00 | 12.00 | -532.00 | 0.4700 | 46.3847 | 0.0000 | 0.7850 | 0.1366 | 0.0175 | 0.0129 | 1.5477 | 190.00 | ||
| Alnylam Pharmaceuticals, Inc. ALNY | 246.80 | -1.99 -0.80% | 676 vs. 859 | 31,832.00 | 494.00 | -65.00 | -94.00 | -7,075.00 | -0.5200 | -73.3326 | 0.0000 | 0.8665 | -0.1334 | 0.3007 | -0.0172 | 2.8593 | 128.00 | ||
| Vaxcyte, Inc. PCVX | 88.39 | 2.43 2.83% | 1,980 vs. 1,214 | 11,016.00 | 0.00 | -95.00 | -171.00 | -1,019.00 | -0.8500 | -19.6094 | 0.0000 | 0.0000 | 0.0000 | -0.0479 | -0.0454 | 17.2498 | 124.00 | ||
| Apellis Pharmaceuticals, Inc. APLS | 27.75 | 0.26 0.95% | 1,488 vs. 2,868 | 3,451.00 | 172.00 | -66.00 | -133.00 | -2,903.00 | -0.5400 | -27.6326 | 0.0000 | 0.8802 | -0.3855 | -0.2491 | -0.0798 | 2.7985 | 124.00 | ||
| Seagen Inc. SGEN | 228.74 | -0.16 -0.07% | 19,392 vs. 1,634 | 43,154.00 | 648.00 | -215.00 | -79.00 | -2,756.00 | -1.1500 | -46.2406 | 0.0000 | 0.7452 | -0.3327 | -0.0846 | -0.0594 | 1.9572 | 188.00 | ||
| Bio-Techne Corporation TECH | 71.05 | 2.33 3.39% | 1,303 vs. 915 | 11,289.00 | 303.00 | 49.00 | 64.00 | 1,297.00 | 0.3100 | 55.6413 | 0.0012 | 0.6764 | 0.1617 | 0.0244 | 0.0180 | 2.4910 | 158.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.